

ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody

Package: 100 μl, 50 μl Store at: -20°C

Summary

Product Description	Rabbit Polyclonal antibody recognizes NFkB p100 / p52 phospho (Ser866)
Tested Reactivity	Hu, Ms, Rat
Tested Application	ICC/IF, IHC-P, WB
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Target Name	NFkB p100 / p52
Species	Human
Immunogen	Peptide sequence around phosphorylation site of serine 866(E-D-S(p)-A-Y) derived from Human NFкB- p100/p52.
Conjugation	Un-conjugated
Alternate Names	LYT-10; NF-kB2; DNA-binding factor KBF2; Nuclear factor NF-kappa-B p100 subunit; p100; LYT10; Lymphocyte translocation chromosome 10 protein; Lyt10; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2; Oncogene Lyt-10; H2TF1; CVID10; p52

Application Instructions

Application table	Application	Dilution
	ICC/IF	1:100 - 1:200
	IHC-P	1:50 - 1:100
	WB	1:500 - 1:1000
Application Note	* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.	

Properties


Form	Liquid
Purification	Antibodies were produced by immunizing rabbits with KLH-conjugated synthetic phosphopeptide. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. In addition, non-phospho specific antibodies were removed by chromatogramphy using non- phosphopeptide.
Buffer	PBS (without Mg2+ and Ca2+, pH 7.4), 150mM NaCl, 0.02% Sodium azide and 50% Glycerol.
Preservative	0.02% Sodium azide
Stabilizer	50% Glycerol
Concentration	1 mg/ml

Bioinformation

Database links	GeneID: 18034 Mouse
	GenelD: 4791 Human
	Swiss-port # Q00653 Human
	Swiss-port # Q9WTK5 Mouse
Gene Symbol	NFKB2
Gene Full Name	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
Background	NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B binibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of bto h52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are
Function	NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p


	major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. [UniProt]
Research Area	Cancer antibody; Cell Biology and Cellular Response antibody; Cell Death antibody; Gene Regulation antibody; Signaling Transduction antibody
Calculated Mw	97 kDa
PTM	While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing. Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing. Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.

Images




ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody WB image

Western blot: Extracts from ovary cancer cells stained with ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody.



ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody ICC/IF image

Immunofluorescence: methanol-fixed HeLa cells stained with ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody (red).



ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody IHC-P image

Immunohistochemistry: Paraffin- embedded Human breast carcinoma tissue stained with ARG51519 anti-NFkB p100 / p52 phospho (Ser866) antibody.